z-logo
open-access-imgOpen Access
Total and free prostate‐specific antigen indexes in prostate cancer screening: value and limitation for Japanese populations
Author(s) -
Hara Noboru,
Kitamura Yasuo,
Saito Toshihiro,
Komatsubara Shuichi
Publication year - 2006
Publication title -
asian journal of andrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.701
H-Index - 74
eISSN - 1745-7262
pISSN - 1008-682X
DOI - 10.1111/j.1745-7262.2006.00155.x
Subject(s) - medicine , prostate cancer , urology , prostate specific antigen , prostate , receiver operating characteristic , gynecology , nuclear medicine , cancer
Aim: To assess the efficacy and limitation of free/total prostate‐specific antigen ratio (f/tPSA) at a single institution in Japan, focusing on the avoidance of pointless prostate biopsies. Methods : In total, 631 men between 44 and 93 years old (mean 69.8 years) with elevated PSA underwent power‐Doppler ultrasoundgraphy‐guided transrectal 10‐core prostate biopsies at Niigata Cancer Center Hospital, and their histological features were investigated with total PSA (tPSA) and f/tPSA. Results : PCa was detected in 126 of 134 patients (94.3%) with tPSA of 26 ng/mL or higher. The detection rate was 59.4% for tPSA of 21–25 ng/mL, followed by 39.2% for 16–20 ng/mL, 30.0% for 11–15 ng/mL, 20.0% for 4.1–10 ng/mL and 7.6% for ≤ 4.0 ng/mL. f/tPSA of the PCa group was significantly lower than that of non‐malignamt disorders in any tPSA ranges (mean 0.122 vs. 0.160, P < 0.001). Receiver‐operating characteristics analyses showed that f/tPSA (AUC: 0.664) performed more valuably than tPSA (AUC: 0.559) in patients with tPSA between 3.0–10 ng/mL ( P < 0.01). Although f/tPSA of 0.250 for the cut‐off value might miss 1.8% PCa patients, it potentially spares 9.2% of unnecessary biopsies. Conclusion : f/tPSA is more valuable compared with tPSA alone for the prediction of the occurrence of PCa. We recommend 0.250 as the cut‐off value for f/tPSA in PCa screening for Asian men having so‐called grey‐zone tPSA.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here